The central question of type 2 diabetes (Q38162978)

30 August 2017

title

The central question of type 2 diabetes (English)

1 reference

30 August 2017

1 reference

Thaïs Rouquet

1 reference

30 August 2017

Marion S Bonnet

1 reference

30 August 2017

Clément Pierre

1 reference

30 August 2017

Michel Dallaporta

1 reference

30 August 2017

Jean-Denis Troadec

1 reference

30 August 2017

Julien Roux

1 reference

30 August 2017

Bruno Bariohay

1 reference

30 August 2017

publication date

1 May 2013

1 reference

Pharmaceutical patent analyst

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

399-427

1 reference

Global estimates of the prevalence of diabetes for 2010 and 2030

30 August 2017

cites work

1 reference

Globalization of diabetes: the role of diet, lifestyle, and genes

21 January 2018

1 reference

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

Intracellular organization of insulin signaling and GLUT4 translocation

21 January 2018

1 reference

Control of glycogen deposition.

21 January 2018

1 reference

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

AMP-activated protein kinase--development of the energy sensor concept.

21 January 2018

1 reference

Brain glucose sensing, counterregulation, and energy homeostasis

21 January 2018

1 reference

Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats.

21 January 2018

1 reference

Hypothalamic insulin signaling is required for inhibition of glucose production

21 January 2018

1 reference

Role of brain insulin receptor in control of body weight and reproduction

21 January 2018

1 reference

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

21 January 2018

1 reference

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

21 January 2018

1 reference

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

21 January 2018

1 reference

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

21 January 2018

1 reference

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

21 January 2018

1 reference

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

Effects of the obese gene product on body weight regulation in ob/ob mice

21 January 2018

1 reference

Central nervous control of energy and glucose balance: focus on the central melanocortin system

21 January 2018

1 reference

Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities

21 January 2018

1 reference

Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice

21 January 2018

1 reference

Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview.

21 January 2018

1 reference

Identification of nesfatin-1 as a satiety molecule in the hypothalamus

21 January 2018

1 reference

CCK-8S activates c-Fos in a dose-dependent manner in nesfatin-1 immunoreactive neurons in the paraventricular nucleus of the hypothalamus and in the nucleus of the solitary tract of the brainstem

21 January 2018

1 reference

Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus

21 January 2018

1 reference

Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans

21 January 2018

1 reference

Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats

21 January 2018

1 reference

The novel function of nesfatin-1: anti-hyperglycemia

21 January 2018

1 reference

Central NUCB2/Nesfatin-1-expressing neurones belong to the hypothalamic-brainstem circuitry activated by hypoglycaemia.

21 January 2018

1 reference

Molecular mechanisms of insulin resistance in type 2 diabetes mellitus

21 January 2018

1 reference

Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver

21 January 2018

1 reference

Insulin resistance and pancreatic beta cell failure

21 January 2018

1 reference

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study

21 January 2018

1 reference

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance

21 January 2018

1 reference

Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage?

21 January 2018

1 reference

Islet amyloid polypeptide, islet amyloid, and diabetes mellitus

21 January 2018

1 reference

Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function

21 January 2018

1 reference

Hepatitis C virus infection: molecular pathways to insulin resistance

21 January 2018

1 reference

Impact of liver diseases on the development of type 2 diabetes mellitus

21 January 2018

1 reference

Biotechnological and administration innovations in insulin therapy

21 January 2018

1 reference

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

21 January 2018

1 reference

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

21 January 2018

1 reference

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

DPP IV inhibitors: successes, failures and future prospects

21 January 2018

1 reference

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

Cellular and molecular mechanisms of metformin: an overview

21 January 2018

1 reference

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

21 January 2018

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats

21 January 2018

1 reference

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action

21 January 2018

1 reference

Assessing the potential of glucokinase activators in diabetes therapy

21 January 2018

1 reference

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

21 January 2018

1 reference

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

21 January 2018

1 reference

SGLT-2 inhibitors in development for type 2 diabetes treatment

21 January 2018

1 reference

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target

21 January 2018

1 reference

Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice

21 January 2018

1 reference

Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization

21 January 2018

1 reference

An update in the management of obesity: the weight of CNS targets

21 January 2018

1 reference

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

21 January 2018

1 reference

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice

21 January 2018

1 reference

Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.

21 January 2018

1 reference

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

21 January 2018

1 reference

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety

21 January 2018

1 reference

Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes

21 January 2018

1 reference

Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance

21 January 2018

1 reference

Leptin enters the brain by a saturable system independent of insulin

21 January 2018

1 reference

Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance

21 January 2018

1 reference

In vitro demonstration of a saturable transport system for leptin across the blood-brain barrier

21 January 2018

1 reference

The blood-brain barrier as a cause of obesity

21 January 2018

1 reference

Decreased blood-brain leptin transfer in an ovine model of obesity and weight loss: resolving the cause of leptin resistance

21 January 2018

1 reference

Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein downregulation.

21 January 2018

1 reference

Region-specific leptin resistance within the hypothalamus of diet-induced obese mice.

21 January 2018

1 reference

Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment

21 January 2018

1 reference

Amylinergic control of food intake

21 January 2018

1 reference

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression

21 January 2018

1 reference

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms

21 January 2018

1 reference

Mechanisms of amylin/leptin synergy in rodent models

21 January 2018

1 reference

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

21 January 2018

1 reference

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development

21 January 2018

1 reference

The role of melanocyte-stimulating hormone in insulin resistance and type 2 diabetes mellitus

21 January 2018

1 reference

The central melanocortin system directly controls peripheral lipid metabolism

21 January 2018

1 reference

Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle

21 January 2018

1 reference

Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats

21 January 2018

1 reference

Weighing in the role of BDNF in the central control of eating behavior

21 January 2018

1 reference

Brain-Derived Neurotrophic Factor Reduces Blood Glucose Level in Obese Diabetic Mice but Not in Normal Mice

21 January 2018

1 reference

Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice

21 January 2018

1 reference

Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice

21 January 2018

1 reference

Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice

21 January 2018

1 reference

Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice

21 January 2018

1 reference

The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice

21 January 2018

1 reference

Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice

21 January 2018

1 reference

In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140.

21 January 2018

1 reference

Epitope mapping of secreted mouse leptin utilizing peripherally administered synthetic peptides

21 January 2018

1 reference

Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels

21 January 2018

1 reference

The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice

21 January 2018

1 reference

Intranasal delivery of mouse [D‐Leu‐4]‐OB3, a synthetic peptide amide with leptin‐like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin‐resistant C57BLK/6‐m db/db mice

21 January 2018

1 reference

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice

21 January 2018

1 reference

Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice

21 January 2018

1 reference

Leptin-dependent control of glucose balance and locomotor activity by POMC neurons.

21 January 2018

1 reference

Leptin deficiency causes insulin resistance induced by uncontrolled diabetes

21 January 2018

1 reference

Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice

21 January 2018

1 reference

TrkB agonists ameliorate obesity and associated metabolic conditions in mice

21 January 2018

1 reference

Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates.

21 January 2018

1 reference

Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway

21 January 2018

1 reference

Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain

21 January 2018

1 reference

G protein-coupled receptor 12 deficiency results in dyslipidemia and obesity in mice

21 January 2018

1 reference

A role for melanin-concentrating hormone in the central regulation of feeding behaviour

21 January 2018

1 reference

Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance

21 January 2018

1 reference

Mice lacking melanin-concentrating hormone are hypophagic and lean

21 January 2018

1 reference

Melanin-concentrating hormone induces insulin resistance through a mechanism independent of body weight gain

21 January 2018

1 reference

MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance.

21 January 2018

1 reference

Melanin concentrating hormone is a novel regulator of islet function and growth.

21 January 2018

1 reference

Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity

21 January 2018

1 reference

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/PPA.13.22

1 reference

30 August 2017

1 reference